公开(公告)号：US20240285740A1

公开(公告)日：2024-08-29

申请号：US18289780

申请日：2022-05-09

Applicant: Dana-Farber Cancer Institute, Inc.

Inventor： Kenneth C. Anderson ,  Jooeun Bae

IPC: A61K39/00 ,  A61K9/51 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K39/001152 ,  A61K9/51 ,  A61K38/1774 ,  A61K39/001111 ,  A61K39/001129 ,  A61K39/3955 ,  A61K39/4611 ,  A61K45/06 ,  A61P35/00 ,  A61K2039/54 ,  A61K2039/542 ,  A61K2039/543

Abstract: This disclosure features human Lymphocyte-activation gene 3 (LAG3) and human Galectin-3 (GAL3) inhibitory agents, immunogenic peptides X-Box Binding Protein 1 (XBP1), CD2 Subset 1 (CS1), and CD138 peptides, and methods of using the inhibitory agents and peptides to treat blood cancers and pre-cancerous conditions.

公开(公告)号：US12016910B2

公开(公告)日：2024-06-25

申请号：US17043192

申请日：2019-04-11

Applicant: ENTEROME S.A.

Inventor： Laurent Chene ,  Christophe Bonny ,  Francesco Strozzi

IPC: A61K39/00 ,  A61P35/00

CPC classification number: A61K39/001119 ,  A61K39/00115 ,  A61K39/001152 ,  A61K39/001154 ,  A61P35/00 ,  A61K2039/55566

Abstract: The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides antigenic peptides, which are distinct from, but have amino acid similarity to, fragments of human tumor antigens. The present invention further provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.

公开(公告)号：US20230364212A1

公开(公告)日：2023-11-16

申请号：US18170994

申请日：2023-02-17

Applicant: Think Therapeutics, Inc.

Inventor： David Kenneth GIFFORD ,  Brandon CARTER

IPC: A61K39/00 ,  A61K38/08 ,  A61K38/10 ,  C07K7/06 ,  C07K7/08 ,  A61P35/00

CPC classification number: A61K39/00116 ,  A61K38/08 ,  A61K38/10 ,  A61K39/001152 ,  A61K39/001158 ,  C07K7/06 ,  C07K7/08 ,  A61P35/00 ,  A61K2039/86 ,  A61K48/00

Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

公开(公告)号：US12059463B2

公开(公告)日：2024-08-13

申请号：US16758682

申请日：2018-10-23

Applicant: ONCOPEP, INC.

Inventor： Doris Peterkin ,  Marc A. Cohen

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61K39/001111 ,  A61K39/001152 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55566

Abstract: The disclosure features, inter alia, combination therapies comprising pembrolizumab and one or more immunogenic XBP1-, CD138-, and CS1-derived peptides. The therapies herein can be used, e.g., for inducing an immune response in a subject having a cancer, and treating a cancer such as breast cancer, e.g., triple negative breast cancer.

公开(公告)号：US20230414735A1

公开(公告)日：2023-12-28

申请号：US18311158

申请日：2023-05-02

Applicant: BioNTech US Inc.

Inventor： Michael Steven Rooney

IPC: A61K39/00 ,  A61P35/04 ,  A61P35/00 ,  A61K45/06 ,  C07K14/47 ,  C12N9/00 ,  C07K14/705 ,  C07K4/12

CPC classification number: A61K39/001164 ,  A61P35/04 ,  A61P35/00 ,  A61K39/001103 ,  A61K39/001151 ,  A61K39/001108 ,  A61K39/001107 ,  A61K39/001163 ,  A61K39/001106 ,  A61K39/001162 ,  A61K39/001104 ,  A61K39/0011 ,  A61K45/06 ,  C07K14/4748 ,  A61K39/001102 ,  A61K39/001134 ,  A61K39/001154 ,  C12N9/00 ,  C07K14/47 ,  C07K14/705 ,  C07K4/12 ,  A61K39/001152 ,  A61K2039/812 ,  A61K2039/836 ,  A61K2039/5158 ,  A61K2039/82 ,  A61K2039/505 ,  A61K2039/828 ,  A61K2039/804 ,  A61K38/00

Abstract: The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

公开(公告)号：US20230390370A1

公开(公告)日：2023-12-07

申请号：US18328209

申请日：2023-06-02

Applicant: William Gillanders ,  William Hawkins ,  Simon Goedegebuure ,  Hui Peng ,  Lijin Li

Inventor： William Gillanders ,  William Hawkins ,  Simon Goedegebuure ,  Hui Peng ,  Lijin Li

IPC: A61K39/00 ,  A61P35/00 ,  A61K39/395

CPC classification number: A61K39/001152 ,  A61P35/00 ,  A61K39/3955 ,  A61K39/39566 ,  A61K39/0011 ,  A61K2039/53 ,  A61K2039/852 ,  A61K2039/585

Abstract: The present disclosure is directed to compositions and methods for treating pancreatic cancer. A method of treating pancreatic cancer includes administering a therapeutically effective amount of a composition including a neoantigen vaccine including at least one pancreatic cancer-associated neoantigen and at least one immune checkpoint inhibitor. The methods and compositions of the present disclosure are particularly useful for inducing a neoantigen-specific CD4 or CD8 T cell response against a tumor.

公开(公告)号：US20230181708A1

公开(公告)日：2023-06-15

申请号：US17887444

申请日：2022-08-13

Applicant: Khloris Biosciences, Inc.

Inventor： Nigel G. Kooreman ,  Stephen D. Wolpe ,  Lynne A. Bui

IPC: A61K39/00 ,  A61K39/39 ,  A61K41/17 ,  A61P35/00

CPC classification number: A61K39/001152 ,  A61K39/39 ,  A61K41/17 ,  A61P35/00 ,  A61K2039/5156 ,  A61K2039/5555 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/55516 ,  A61K2039/55544

Abstract: In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.

公开(公告)号：US20180222951A1

公开(公告)日：2018-08-09

申请号：US15749214

申请日：2016-08-03

Applicant: The United States of America,as represented by the Secretary, Department of Health and human Service

Inventor： Jeffrey Schlom ,  Claudia M. Palena

IPC: C07K14/47 ,  A61K38/17 ,  A61K45/06 ,  A61K38/19 ,  A61K9/127 ,  A61P35/00 ,  C12N15/86 ,  A61K39/00

CPC classification number: C07K14/4702 ,  A61K9/127 ,  A61K38/1709 ,  A61K38/193 ,  A61K39/0011 ,  A61K39/001152 ,  A61K39/00117 ,  A61K39/001182 ,  A61K45/06 ,  A61K2039/5256 ,  A61K2039/70 ,  A61P35/00 ,  C12N15/86 ,  C12N2710/10043 ,  Y02A50/466

Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.

公开(公告)号：US12049639B2

公开(公告)日：2024-07-30

申请号：US18174013

申请日：2023-02-24

Applicant: The USA as represented by the Secretary, Department of Health and Human Services

Inventor： Deb K. Chatterjee ,  Stanislaw J. Kaczmarczyk

IPC: C12N15/86 ,  A61K39/00 ,  A61K39/12 ,  A61K45/06 ,  C12N7/00

CPC classification number: C12N15/86 ,  A61K39/0011 ,  A61K39/001117 ,  A61K39/001124 ,  A61K39/001129 ,  A61K39/001144 ,  A61K39/001152 ,  A61K39/001163 ,  A61K39/001181 ,  A61K39/001182 ,  A61K39/001191 ,  A61K39/001194 ,  A61K39/12 ,  A61K45/06 ,  C12N7/00 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/585 ,  C12N2740/11023 ,  C12N2740/11042 ,  C12N2770/36123 ,  C12N2770/36134 ,  C12N2770/36143 ,  C12N2770/36145 ,  C12N2770/36152 ,  C12N2770/36171 ,  C12N2800/24 ,  C12N2810/6081

Abstract: Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alphavirus structural protein gene.

公开(公告)号：US12042531B2

公开(公告)日：2024-07-23

申请号：US17451607

申请日：2021-10-20

Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

Inventor： Mary L. Disis ,  Denise Cecil ,  Meredith Slota

IPC: C12N15/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C12N9/10 ,  C12N15/62 ,  A61K48/00

CPC classification number: A61K39/0011 ,  A61K39/001103 ,  A61K39/001106 ,  A61K39/001129 ,  A61K39/00115 ,  A61K39/001152 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70567 ,  C07K14/70596 ,  C07K14/71 ,  C12N9/104 ,  C12N15/62 ,  C12Y203/02 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/572 ,  A61K48/00

Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.